• Nadim Taheri, Arthur Mageau, Marie-Paule Chauveheid, Antoine Dossier, Fatima Farhi, Celine Mendes, Thomas Papo, Tiphaine Goulenok, and Karim Sacre.
• Service de Médecine Interne, Hôpital Bichat, Assistance Publique Hôpitaux de Paris, Paris, France.
• Eur. J. Intern. Med. 2023 Mar 1; 109: 687268-72.

ObjectiveQuality indicators (QIs) for systemic lupus erythematosus (SLE) management based on the 2019 update of European League Against Rheumatism (EULAR) recommendations have been recently proposed. We aimed to determine whether adherence to QIs was associated with patient reported outcome (PRO).MethodsAdherence to a set of 18 EULAR-based QIs and correlation with PRO assessed by Lupus Impact Tracker (LIT) was tested in a cohort of 162 SLE patients.ResultsOn average, SLE patients received 41% (33; 52.5) of recommended care. Higher adherence to monitoring-related QIs was associated with an older age, a shorter SLE disease duration and a more severe disease (i.e. Class III/IV/V nephritis). LIT demonstrated that the average impact of lupus on patients' life was of 30% (12.5;47.5). In multivariable analysis, patients of female gender (OR 0.25, 95% 0.05-0.94; p = 0.05), with lupus CNS (OR 0.33, 95%CI 0.08-1.05; p = 0.08) and skin involvements (OR 0.49, 95%CI 0.23-1.04; p = 0.07) had higher odds of experiencing a negative impact of the lupus on their life. No association were found between adherences to QIs by physicians and reported quality of life in lupus patients.ConclusionOur study confirms a variable degree of clinicians' adherence to QIs for SLE and shows no clear association between QIs adherence and patient reported outcome. Adherence to QIs by physicians are not enough to impact the quality of life of patients.Copyright © 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

11 keywords...

hide…